Developer docs
API playgroundTry for free, no card

Search company profiles

Multilab

Full company profile

uuid002yiuc

Namestring
Multilab
Legal namestring
MULTILAB INDUSTRIA E COMERCIO DE PRODUTOS FARM LTDA
Websiteurl
multilab.com.br
Company typeenum
Private
Founded yearint
1989
Descriptiontext

Multilab is a Brazilian pharmaceutical manufacturer specializing in generic and similar medicines (medicamentos similares), founded in 1989 and headquartered in Campinas, São Paulo. The company is wholly owned by Grupo NC, one of the largest pharmaceutical conglomerates in Latin America. Multilab operates with approximately 550 professionals engaged in research, development, production, and distribution across multiple therapeutic classes, including analgesics, anti-inflammatories, antihistamines, scabicides, and flu/cold formulations. The portfolio spans prescription-required (tarjados) products and over-the-counter (isentos de prescrição) SKUs, with flagship brands including the Resfegripe family (flu/cold), Buprovil (ibuprofen-based analgesic/anti-inflammatory), Keltrina Plus (permethrin-based scabicide), Aleradina, and Acalmil. All products hold ANVISA Ministry of Health registrations and are produced under GMP-compliant manufacturing authorization.

The company's go-to-market is exclusively B2B2C, distributing through pharmaceutical wholesalers and retailers to reach more than 87,000 points of sale across Brazil. Multilab's commercial strategy is anchored on traditional retail pharmacy channels rather than direct-to-consumer or e-commerce platforms, with consumer-facing engagement limited to packaging information and a digital package-insert partnership with Sara (bula digital). Recent commercial activity centers on brand refreshes and line extensions rather than category expansion — including a 2025 Buprovil rebrand and the June 2026 launch of ResfeGripe Mel e Limão in sachet format.

Multilab generates revenue through one-time sales of pharmaceutical products to wholesalers and distributors, with no disclosed subscription, licensing, or platform model. Pricing is set through standard retail pharmacy channels and is not publicly disclosed. In 2025 the company achieved Great Place to Work certification (2025-2026) and proactively executed a voluntary recall of one lot of Solifenacin Succinate due to a packaging printing error, reflecting operational maturity in regulatory and quality management.

Short descriptiontext

Multilab is a Brazilian manufacturer of generic and similar medicines, owned by Grupo NC, producing prescription and OTC pharmaceuticals across multiple therapeutic classes for distribution to over 87,000 retail points of sale in Brazil.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSão Jerônimo, Brazil
HQ citystring
São Jerônimo
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, OTC medications, similar medicines Brazil, pharmaceutical manufacturing, flu and cold remedies
Industry5 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIADAB
Cold, Flu & Cough Remedies
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Multilab generates revenue through the manufacture and sale of generic and similar medicines (medicamentos similares), including both prescription (tarjados) and over-the-counter (isentos de prescricao) products across multiple therapeutic categories including analgesics, anti-inflammatories, antihistamines, and scabicides.

multilab.com.br
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1ResfeGripe
Description

Over-the-counter medication for treating symptoms of flu and colds, including nasal congestion, runny nose, fever, headache, and body aches. Available in capsule and sachet forms.

multilab.com.br
+4 more records
Core offering1 text field

Multilab manufactures and distributes generic and similar medicines (medicamentos similares) across diverse therapeutic classes including analgesics, anti-inflammatories, antihistamines, flu/cold remedies, and scabicides. The company produces both prescription (tarjados) and over-the-counter (isentos de prescrição) pharmaceutical products, with a portfolio including Resfegripe, Buprovil, Keltrina Plus, Acalmil, and Aleradina. Products are distributed through pharmaceutical wholesalers to over 87,000 points of sale across Brazil.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Multilab is a Brazilian pharmaceutical company with over 35 years of market experience, operating as part of Grupo NC, one of the largest pharmaceutical groups in Latin America. The company operates with approximately 550 professionals engaged in research, development, production, and distribution of medicines. Multilab maintains a broad portfolio spanning diverse therapeutic classes and pharmaceutical forms, divided into prescription-required (tarjados) and over-the-counter (isentos de prescrição) product lines. The product portfolio includes: Resfegripe family (flu/cold medications in capsule, tablet, and sachet formats including Resfegripe Sinus and ResfeGripe Mel e Limão variants); Buprovil family (ibuprofen-based anti-inflammatory, analgesic, and antipyretic medications in tablet and pediatric drops formats); Keltrina Plus (permethrin-based scabicide for scabies treatment); plus Acalmil and Aleradina OTC products. Distribution reaches over 87,000 sales points across Brazil.

Product and service9 records
1Resfegripe
CategoryOTC pharmaceutical - flu and cold remedies
Description

Over-the-counter medication for treating flu and cold symptoms, including nasal congestion, runny nose, fever, headache, and muscle aches. Contains paracetamol 400mg, chlorpheniramine maleate 4mg, and phenylephrine hydrochloride 4mg. Registration MS 1.1819.0268.

2Resfegripe Sinus
CategoryOTC pharmaceutical - flu and cold remedies
Description

Variant of Resfegripe specifically formulated for sinus symptoms associated with flu and colds.

3Resfegripe Mel e Limão
CategoryOTC pharmaceutical - flu and cold remedies
Description

New honey and lemon flavored variant of Resfegripe available in sachet format for flu and cold symptom relief.

4Buprovil
CategoryOTC pharmaceutical - anti-inflammatory and analgesic
Description

Ibuprofen-based medication with anti-inflammatory, analgesic, and antipyretic properties. Available in 300mg and 600mg tablets. Registration MS 1.1819.0061.

5Buprovil Gotas
CategoryOTC pharmaceutical - pediatric anti-inflammatory
Description

Pediatric ibuprofen drops suspension for children, available in 50mg/ml (30ml bottle) and 100mg/ml (20ml bottle) concentrations.

6Keltrina Plus
CategoryOTC pharmaceutical - scabicide/parasiticide
Description

Permethrin-based scabicide and ectoparasiticide cream emulsion (50mg/ml, 5%) for treatment of scabies (sarna), presented in 60ml bottles. Registration MS 1.1819.0001.002-7.

7Acalmil
CategoryOTC pharmaceutical
Description

Over-the-counter pharmaceutical product. Category and specific indications require further detail from product packaging.

8Aleradina
CategoryOTC pharmaceutical - antihistamine
Description

Over-the-counter syrup medication targeting symptoms related to allergies.

9SUCCINATO DE SOLIFENACINA
CategoryPrescription pharmaceutical
Description

Prescription medication (10mg, 30 tablets) subject to voluntary recall (lot 4T4420) due to printing error on dosage packaging. Registration MS number available.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSupportingTypeTechnology or Integration
Description

Multilab partners with Sara to provide digital package insert (bula digital) services, allowing consumers to access medication information digitally through Sara's platform.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global generic pharmaceutical leader with presence across Latin America. Comparable as a broad incumbent competing in the same generic/similar OTC categories with global scale.

2EMS
TypeDirect peer
Description

Brazil's largest pharmaceutical company by units sold and a leading generic/similar medicines manufacturer. Directly comparable as a Brazilian OTC and generic competitor sharing Grupo NC's Mercado Farma distribution platform referenced on Multilab's own site.

TypeDirect peer
Description

Major Brazilian generic and OTC pharmaceutical manufacturer with broad retail distribution. Highly comparable to Multilab in target categories (analgesics, cold/flu, allergy) and consumer pricing positioning in Brazil.

TypeEmerging player
Description

Indian-headquartered global generic manufacturer with growing Brazil and LatAm operations. Comparable as a low-cost generic competitor targeting similar therapeutic classes.

TypeDirect peer
Description

Brazilian pharmaceutical company with a strong OTC and prescription portfolio. Comparable as a domestic competitor in analgesics, anti-inflammatories, and consumer health categories.

TypeDirect peer
Description

Brazilian pharmaceutical manufacturer with prescription and OTC products distributed nationally. Comparable scale and distribution model targeting Brazilian retail pharmacies.

TypeDirect peer
Description

Brazilian generic pharmaceutical brand owned by Sanofi, focused on prescription and OTC generics. Direct comparable in the Brazilian generic/similar medicines segment.

TypeBroad incumbent
Description

Global generics and specialty pharmaceutical company formed by Mylan-Upjohn combination. Comparable in OTC and generic therapeutic categories with multinational distribution.

9Eurofarma
TypeDirect peer
Description

Brazilian multinational pharmaceutical manufacturer with a generics, similars, and OTC portfolio across Latin America. Comparable business model (manufacturing + distribution) and overlapping therapeutic categories.

TypeBroad incumbent
Description

Largest Brazilian pharmaceutical company by revenue and a major OTC player (brands like Benegrip, Epocler). Comparable as a Brazilian incumbent in the same OTC categories Multilab competes in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Multilab

Generic Pharmaceuticalsmultilab.com.br

Multilab is a Brazilian manufacturer of generic and similar medicines, owned by Grupo NC, producing prescription and OTC pharmaceuticals across multiple therapeutic classes for distribution to over 87,000 retail points of sale in Brazil.

What Multilab does

Multilab is a Brazilian pharmaceutical manufacturer specializing in generic and similar medicines (medicamentos similares), founded in 1989 and headquartered in Campinas, São Paulo. The company is wholly owned by Grupo NC, one of the largest pharmaceutical conglomerates in Latin America. Multilab operates with approximately 550 professionals engaged in research, development, production, and distribution across multiple therapeutic classes, including analgesics, anti-inflammatories, antihistamines, scabicides, and flu/cold formulations. The portfolio spans prescription-required (tarjados) products and over-the-counter (isentos de prescrição) SKUs, with flagship brands including the Resfegripe family (flu/cold), Buprovil (ibuprofen-based analgesic/anti-inflammatory), Keltrina Plus (permethrin-based scabicide), Aleradina, and Acalmil. All products hold ANVISA Ministry of Health registrations and are produced under GMP-compliant manufacturing authorization.

The company's go-to-market is exclusively B2B2C, distributing through pharmaceutical wholesalers and retailers to reach more than 87,000 points of sale across Brazil. Multilab's commercial strategy is anchored on traditional retail pharmacy channels rather than direct-to-consumer or e-commerce platforms, with consumer-facing engagement limited to packaging information and a digital package-insert partnership with Sara (bula digital). Recent commercial activity centers on brand refreshes and line extensions rather than category expansion — including a 2025 Buprovil rebrand and the June 2026 launch of ResfeGripe Mel e Limão in sachet format.

Multilab generates revenue through one-time sales of pharmaceutical products to wholesalers and distributors, with no disclosed subscription, licensing, or platform model. Pricing is set through standard retail pharmacy channels and is not publicly disclosed. In 2025 the company achieved Great Place to Work certification (2025-2026) and proactively executed a voluntary recall of one lot of Solifenacin Succinate due to a packaging printing error, reflecting operational maturity in regulatory and quality management.

Multilab firmographics

Firmographics
Name
Multilab
Legal name
MULTILAB INDUSTRIA E COMERCIO DE PRODUTOS FARM LTDA
Website
https://multilab.com.br
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Multilab is a Brazilian manufacturer of generic and similar medicines, owned by Grupo NC, producing prescription and OTC pharmaceuticals across multiple therapeutic classes for distribution to over 87,000 retail points of sale in Brazil.
Ownership category
akta.pro rank

Multilab industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIADAB
Cold, Flu & Cough Remedies
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Generic pharmaceuticals
  • OTC medications
  • Similar medicines Brazil
  • Pharmaceutical manufacturing
  • Flu and cold remedies

Where Multilab is headquartered

Location

Headquarters

HQ city
São Jerônimo
HQ country
Brazil
HQ region
Latin America

Offices1 record

Markets served

Multilab business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Multilab generates revenue through the manufacture and sale of generic and similar medicines (medicamentos similares), including both prescription (tarjados) and over-the-counter (isentos de prescricao) products across multiple therapeutic categories including analgesics, anti-inflammatories, antihistamines, and scabicides.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Multilab product offering

Product offering

Core offering

Multilab manufactures and distributes generic and similar medicines (medicamentos similares) across diverse therapeutic classes including analgesics, anti-inflammatories, antihistamines, flu/cold remedies, and scabicides. The company produces both prescription (tarjados) and over-the-counter (isentos de prescrição) pharmaceutical products, with a portfolio including Resfegripe, Buprovil, Keltrina Plus, Acalmil, and Aleradina. Products are distributed through pharmaceutical wholesalers to over 87,000 points of sale across Brazil.

Product overview

Multilab is a Brazilian pharmaceutical company with over 35 years of market experience, operating as part of Grupo NC, one of the largest pharmaceutical groups in Latin America. The company operates with approximately 550 professionals engaged in research, development, production, and distribution of medicines. Multilab maintains a broad portfolio spanning diverse therapeutic classes and pharmaceutical forms, divided into prescription-required (tarjados) and over-the-counter (isentos de prescrição) product lines. The product portfolio includes: Resfegripe family (flu/cold medications in capsule, tablet, and sachet formats including Resfegripe Sinus and ResfeGripe Mel e Limão variants); Buprovil family (ibuprofen-based anti-inflammatory, analgesic, and antipyretic medications in tablet and pediatric drops formats); Keltrina Plus (permethrin-based scabicide for scabies treatment); plus Acalmil and Aleradina OTC products. Distribution reaches over 87,000 sales points across Brazil.

Differentiator

Problem solved

Functional benefit

Brands

  • ResfeGripe: Over-the-counter medication for treating symptoms of flu and colds, including nasal congestion, runny nose, fever, headache, and body aches. Available in capsule and sachet forms.
  • Buprovil
  • Keltrina
  • Acalmil
  • Aleradina

Products and services

  • Resfegripe Over-the-counter medication for treating flu and cold symptoms, including nasal congestion, runny nose, fever, headache, and muscle aches. Contains paracetamol 400mg, chlorpheniramine maleate 4mg, and phenylephrine hydrochloride 4mg. Registration MS 1.1819.0268.
  • Resfegripe Sinus Variant of Resfegripe specifically formulated for sinus symptoms associated with flu and colds.
  • Resfegripe Mel e Limão New honey and lemon flavored variant of Resfegripe available in sachet format for flu and cold symptom relief.
  • Buprovil Ibuprofen-based medication with anti-inflammatory, analgesic, and antipyretic properties. Available in 300mg and 600mg tablets. Registration MS 1.1819.0061.
  • Buprovil Gotas Pediatric ibuprofen drops suspension for children, available in 50mg/ml (30ml bottle) and 100mg/ml (20ml bottle) concentrations.
  • Keltrina Plus Permethrin-based scabicide and ectoparasiticide cream emulsion (50mg/ml, 5%) for treatment of scabies (sarna), presented in 60ml bottles. Registration MS 1.1819.0001.002-7.
  • Acalmil Over-the-counter pharmaceutical product. Category and specific indications require further detail from product packaging.
  • Aleradina Over-the-counter syrup medication targeting symptoms related to allergies.
  • SUCCINATO DE SOLIFENACINA Prescription medication (10mg, 30 tablets) subject to voluntary recall (lot 4T4420) due to printing error on dosage packaging. Registration MS number available.

Companies that use Multilab

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Multilab technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Multilab partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Sara (Bula Digital)supportingTechnology or IntegrationMultilab partners with Sara to provide digital package insert (bula digital) services, allowing consumers to access medication information digitally through Sara's platform.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Multilab competitors and assessment

Company assessment

Broad incumbents

  • Teva Pharmaceutical Industries: Global generic pharmaceutical leader with presence across Latin America. Comparable as a broad incumbent competing in the same generic/similar OTC categories with global scale.
  • Viatris (Mylan): Global generics and specialty pharmaceutical company formed by Mylan-Upjohn combination. Comparable in OTC and generic therapeutic categories with multinational distribution.
  • Hypera (Hyperapharma): Largest Brazilian pharmaceutical company by revenue and a major OTC player (brands like Benegrip, Epocler). Comparable as a Brazilian incumbent in the same OTC categories Multilab competes in.

Direct peers

  • EMS: Brazil's largest pharmaceutical company by units sold and a leading generic/similar medicines manufacturer. Directly comparable as a Brazilian OTC and generic competitor sharing Grupo NC's Mercado Farma distribution platform referenced on Multilab's own site.
  • Cimed: Major Brazilian generic and OTC pharmaceutical manufacturer with broad retail distribution. Highly comparable to Multilab in target categories (analgesics, cold/flu, allergy) and consumer pricing positioning in Brazil.
  • Aché Laboratórios: Brazilian pharmaceutical company with a strong OTC and prescription portfolio. Comparable as a domestic competitor in analgesics, anti-inflammatories, and consumer health categories.
  • Biolab Farmacêutica: Brazilian pharmaceutical manufacturer with prescription and OTC products distributed nationally. Comparable scale and distribution model targeting Brazilian retail pharmacies.
  • Medley (Sanofi): Brazilian generic pharmaceutical brand owned by Sanofi, focused on prescription and OTC generics. Direct comparable in the Brazilian generic/similar medicines segment.
  • Eurofarma: Brazilian multinational pharmaceutical manufacturer with a generics, similars, and OTC portfolio across Latin America. Comparable business model (manufacturing + distribution) and overlapping therapeutic categories.

Emerging players

  • Aurobindo Pharma: Indian-headquartered global generic manufacturer with growing Brazil and LatAm operations. Comparable as a low-cost generic competitor targeting similar therapeutic classes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Multilab social profiles

Digital presence

Multilab compliance and trust

Trust signal

Compliance2 records

Multilab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Multilab leadership team

Management profile

Number of profiles

Multilab funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Multilab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Multilab

What does Multilab do?

Multilab manufactures and distributes generic and similar medicines (medicamentos similares) across diverse therapeutic classes including analgesics, anti-inflammatories, antihistamines, flu/cold remedies, and scabicides. The company produces both prescription (tarjados) and over-the-counter (isentos de prescrição) pharmaceutical products, with a portfolio including Resfegripe, Buprovil, Keltrina Plus, Acalmil, and Aleradina. Products are distributed through pharmaceutical wholesalers to over 87,000 points of sale across Brazil.

Is Multilab a public or private company?

Multilab is a private company. It is classified as corporate owned and is currently operating.

When was Multilab founded?

Multilab was founded in 1989. It employs 501 to 1,000 people.

Where is Multilab based?

Multilab is headquartered in São Jerônimo, Brazil, in the Latin America region.

How does Multilab make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Multilab's main competitors?

Broad incumbents on record are Teva Pharmaceutical Industries, Viatris (Mylan) and Hypera (Hyperapharma). Direct peers are EMS, Cimed, Aché Laboratórios, Biolab Farmacêutica, Medley (Sanofi) and Eurofarma. Aurobindo Pharma is listed as an emerging player.

Does Multilab have an API?

No public API is recorded for Multilab.

What industry is Multilab in?

Multilab's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIADAB, Cold, Flu & Cough Remedies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales